Zymedyne published in prestigious Journal of experimental Medicine (JEM)
Research conducted in the lab of Zymedyne Co-Founder and CSO Dr. Gerald Zamponi, has now been published in the prestigious Journal of experimental Medicine (JEM). The results of this work validate Zymedyne’s unique target – Cav3.2/USP5, as a potential therapeutic avenue for chronic pain treatment in humans. https://doi.org/10.1084/jem.20241877
Further $100k UCEED investment secured
Zymedyne is excited to announce that the investment arm of the University of Calgary – UCEED, has invested a Further $100k and continues to show its support for our game changing technology by allowing us to continue to use the University of Calgary’s world class research facilities. https://www.ucalgary.ca/uceed/about/portfolio/zymedyne This important investment helps cover the cost of patent applications and helps generate additional funds by allowing us to utilize matching Canadian federal grant applications such as The National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) https://nrc.canada.ca/en/support-technology-innovation/about-nrc-industrial-research-assistance-program
Zymedyne registers new provisional patent application
Zymedyne is pleased to announce that it has successfully filed a new patent application on Tetrahydroquinoline compounds that cover complete Composition of matter and “Use Of”. This application is expected to be WIPO registered in 2025-2026.
$300K Alberta Innovates AICE Grant secured
Zymedyne is very pleased to announce that it has successfully secured a 2yr, $300k Alberta Innovates AICE Grant to pursue new compounds that target Zymedyne’s unique, non-opioid, pain relieving mechanism. This money will be used to create new compounds for patenting and to start independent testing of existing compounds in preliminary safety, tox, and bioavailability tests that are important for achieving IND designation
Zymedyne Therapeutics wins Macquarie University Incubator annual Pitch Final award for Most Valuable Investment 2023
From Macquarie Incubator: “Last week, we held our annual Pitch Final event for 2023! 🧠 We had five startups that delivered excellent pitches: Stopfalls Physio Pty Ltd, Trappi, Lagvelki, Zymedyne Therapeutics and Loop Hydrometallurgy, with three winning the night’s top prizes! Congratulations to our winners: Dave Sammut from Loop Hydrometallurgy won Best Pitch, receiving $3,000! Dr Chris Bladen from Zymedyne Therapeutics won Most Valuable Investment, receiving $5,000! Last but not least, Anna Stackpool from Stopfalls Physio Pty Ltd won the Researchers Engagement award, receiving $25,000 to put towards Macquarie University researchers and HDR students to validate, review and/or conduct commercial research activities! We want to thank our MC, Alistair Booth for helping us run the event, and our judges, Matthew Edmonds, Alan Jones, Jessica Baird Walsh, and Dan Geaves FFIA, who provided their time to listen to our startups pitch and ultimately make a tough decision on the winners. We’d…
Award For Outstanding Innovation – Dr. Ketul Patel
Zymedyne Therapeutics is extremely proud of our Medicinal Chemist Ketulbhai Patel for winning the 2023 Mitacs Award for Outstanding Innovation. Ketul is a brilliant chemist and key part of Zymedyne’s team and thoroughly deserves the national recognition of this award. Zymedyne is also very grateful to the support we receive from Mitacs and hope to continue building the positive partnership we have with them and help grow Canada’s Biotechnology globally! From Mitacs: Prestigious Mitacs Awards Celebrate Canada’s Top Innovators – Mitacs
AZ/NZ TMRRW Award Winner
Zymedyne is pleased to announce that we have won the #Challenger Award in the #Innovation Category at the 2023 Australia New Zealand TMMRW Awards! Click to view the post below: https://www.linkedin.com/posts/connectmpid_macquariepark-ugcPost-7135434121287254016-5c9T?utm_source=share&utm_medium=member_desktop
Zymedyne registers new provisional patent application
Zymedyne is pleased to announce that it has successfully filed a new U.S.patent application on Thiazolidine compounds that cover complete Composition of matter and“Use Of”.
SXSW Sydney Pitch Competiton: 1st Place Award
Zymedyne Therapeutics wins 1st place in the SXSW Sydney pitch competition in the Healthcare, Biotech, Future of Medicine, category. Chris Bladen posted on LinkedIn
Campus Alberta Neuroscience Spotlight
Zymedyne is pleased to announce a spotlight on the Campus Alberta Neuroscience LinkedIn page! From Campus Alberta: “What would you think about an effective pain relief solution that doesn’t cause weight gain, respiratory depression, or addiction? Zymedyne Therapeutics is working on a technology to do just that” View post: https://www.linkedin.com/posts/campus-alberta-neuroscience_zymedyne-therapeutics-activity-6996577577083555841-AyaH?utm_source=li_share&utm_content=feedcontent&utm_medium=g_dt_web&utm_campaign=copy